These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 23538263)

  • 1. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
    Bilotti E
    Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitors in the treatment of multiple myeloma.
    McBride A; Ryan PY
    Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
    van de Donk NW; Lokhorst HM
    Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Shah JJ
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
    Jakubowiak AJ
    Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
    Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
    Moreau P
    Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Carfilzomib-Associated Cardiac Adverse Events.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib in multiple myeloma.
    Andreu-Vieyra C; Berenson JR
    Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Nooka AK
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.